シンガポール - 英語 - HSA (Health Sciences Authority)

agilent technologies singapore (international) pte ltd - pathology - monoclonal mouse anti-human pd-l1, clone 22c3 is intended for use in the detection of pd-l1 protein in formalin-fixed, paraffin-embedded (ffpe) non-small cell lung cancer (nsclc) tissues. monoclonal mouse anti-human pd-l1, clone 22c3 is intended for qualitative pd-l1 testing and indicated as an aid in identifying nsclc patients for treatment with keytruda® (pembrolizumab). pd-l1 protein expression in nsclc is determined by using tumor proportion score (tps), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. the specimen should be considered to have pd-l1 expression if tps ≥ 1% and high pd-l1 expression if tps ≥ 50%.

フィリピン - 英語 - FDA (Food And Drug Administration)

e.l. labs inc - pirenoxine , catalent - tablet w/ solvent for ophthalmic solution - 75mcg+750mcg

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

lifewave, inc. - aconitum napellus (unii: u0nq8555jd) (aconitum napellus - unii:u0nq8555jd), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), avena sativa flowering top (unii: ma9cqj3f7f) (avena sativa flowering top - unii:ma9cqj3f7f), belladonna leaf (unii: 6gzw20tioi) (belladonna leaf - unii:6gzw20tioi), camphor (natural) (unii: n20hl7q941) (camphor (natural) - unii:n20hl7q941), cinchona officinalis bark (unii: s003a158sb) (cinchona officinalis bark - unii:s003a158sb), arabica coffee bean - for the stimulation of acupuncture points for the stimulation of acupuncture points.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - rotavirus g2 human-bovine reassortant, quantity: 1400000 infectious unit/ml; rotavirus g3 human-bovine reassortant, quantity: 1100000 infectious unit/ml; rotavirus g1 human-bovine reassortant, quantity: 1100000 infectious unit/ml; rotavirus g4 human-bovine reassortant, quantity: 1000000 infectious unit/ml; rotavirus p1 [8] human-bovine reassortant, quantity: 1150000 infectious unit/ml - oral liquid - excipient ingredients: polysorbate 80; sucrose; sodium citrate dihydrate; sodium hydroxide; monobasic sodium phosphate; glucose monohydrate; sodium ascorbate; sodium chloride; ammonium metavanadate; calcium chloride dihydrate; cupric sulfate pentahydrate; ferric nitrate nonahydrate; ferrous sulfate heptahydrate; magnesium chloride hexahydrate; dried magnesium sulfate; manganese sulfate tetrahydrate; ammonium molybdate; potassium chloride; sodium acetate; sodium bicarbonate; dibasic sodium phosphate; zinc sulfate heptahydrate; alanine; arginine hydrochloride; asparagine; aspartic acid; cysteine hydrochloride; cystine dihydrochloride; glutamic acid; glycine; histidine hydrochloride monohydrate; hydroxyproline; isoleucine; leucine; lysine hydrochloride; methionine; phenylalanine; proline; serine; threonine; tryptophan; tyrosine disodium; valine; biotin; ergocalciferol; choline chloride; folic acid; inositol; menadione; nicotinamide; nicotinic acid; aminobenzoic acid; calcium pantothenate; pyridoxal hydrochloride; pyridoxine hydrochloride; retinol acetate; riboflavine; dl-alpha-tocopheryl phosphate disodium; thiamine hydrochloride; cyanocobalamin; adenine sulfate dihydrate; adenosine triphosphate disodium; adenosine monophosphate; cholesterol; deoxyribose; glutathione; guanine hydrochloride; sodium hypoxanthine; linoleic acid; alpha lipoic acid; phenolsulfonphthalein; putrescine dihydrochloride; sodium pyruvate; ribose; thymidine; thymine; uracil; sodium xanthine; monoethanolamine; 2-mercaptoethanol; adenosine; uridine; cytidine; guanosine; dexamethasone; epidermal growth factor; hydrocortisone; insulin; alprostadil; liothyronine; ascorbic acid; magnesium sulfate heptahydrate; monobasic sodium phosphate monohydrate; zinc sulfate; arginine; cysteine; cystine; histidine; lysine; tyrosine; adenosine triphosphate; guanine; putrescine - rotateq is indicated for the prevention of rotavirus gastroenteritis (see clinical trials).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

agilent technologies australia pty ltd - ct946 - general laboratory reagent and consumables ivds - anti-fitc-ap cish accessory kit (dako omnis) is intended for the detection of fitc-labeled in situ hybridization (ish) probes following hybridization to formalin-fixed, paraffin-embedded tissue specimens onboard dako omnis.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

agilent technologies australia pty ltd - ct1056 - immunohistology cell marker ivds - pd-l1 ihc 22c3 pharmdx uses mouse anti-human pd-l1, clone 22c3 on ffpe tissue specimens in an automated ihc staining procedure to detect pd-l1. pd-l1 ihc 22c3 pharmdx is a qualitative ihc assay for use in the detection of pd-l1 protein in ffpe cancer tissues on autostainer link 48. it is indicated as an aid in identifying nsclc, hnscc, tnbc and cervical cancer patients for treatment with keytruda? and nsclc patients for treatment with libtayo? according to the approved indication specific pd-l1 expression levels. the trademarks above are owned by their respective owners.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

agilent technologies australia pty ltd - ct1056 - immunohistology cell marker ivds - pd-l1 ihc 22c3 pharmdx is a qualitative immunohistochemical assay using monoclonal mouse anti-pd-l1, clone 22c3 intended for use in the detection of pd-l1 protein in formalin-fixed, paraffin-embedded (ffpe) non-small cell lung cancer (nsclc) tissue, using envision flex visualization system on dako omnis. for in vitro diagnostic use. pd-l1 ihc 22c3 pharmdx is a qualitative immunohistochemical assay using monoclonal mouse anti-pd-l1, clone 22c3 intended for use in the detection of pd-l1 protein in formalin-fixed, paraffin-embedded (ffpe) non-small cell lung cancer (nsclc) tissue, using envision flex visualization system on dako omnis. pd-l1 protein expression in nsclc is determined by using tumor proportion score (tps), which is the percentage of viable tumor cells showing partial or complete membrane staining at any intensity. the specimen should be considered to have pd-l1 expression if tps ? 1%. pd-l1 ihc 22c3 pharmdx is indicated as an aid in identifying nsclc patients for treatment with keytruda? (pembrolizumab). see keytruda? product label for specific clinical circumstances guiding pd-l1 testing.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

agilent technologies australia pty ltd - ct946 - general laboratory reagent and consumables ivds - ivds that are general laboratory reagents, products or consumables, that are intended to be used specifically as an ivd in the testing of specimens within a clinical laboratory.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

agilent technologies australia pty ltd - ct215 - biological stain ivds - dyes, chemicals, stains or solutions that are intended to be used specifically as an ivd, either alone or in combination with others, for the visualisation of structures and/or other intra/extracellular elements in biological tissues. the staining kits are class 2

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

agilent technologies australia pty ltd - ct946 - general laboratory reagent and consumables ivds - general statement : for in vitro diagnostic use by professional user in laboratories and results are evaluated by a pathologist.